Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The SNP rs4588 as well as the triallelic 5-HTTLPR genotypes were in accordance with Hardy: Weinberg equilibrium for SHIP-LEGEND and SHIP-TREND-0.Summary statistics of SHIP-LEGEND and SHIP-TREND by sex.VariableSHIP-LEGEND (n = 1 997)SHIP-TREND-0 (n = 2 939)Combined sample (n = 4 936)Males (n = 957)Females (n = 1 040)Comparison males vs femalesMales (n = 1 447)Females (n = 1 492)Comparison males vs femalesMales (n = 2 404)Females (n = 2 532)Comparison males vs femalesComparison SHIP-LEGEND vs SHIP-TREND-0Age, years (mean(sd))56.8 (14.1)54.1 (13.3)t = 4.5, p < 0.00152.3 (15.3)50.8 (14.9)t = 2.8, p = 0.00554.1 (15.0)52.2 (14.4)t = 4.7, p < 0.001t = 9.1, p < 0.001MDD lifetime (N(%))119 (12.4%)253 (24.3%)χ2 = 46.5 p < 0.001195 (13.5%)338 (22.7%)χ2 = 41.7, p < 0.001314 (13.1%)591 (22.8%)χ2 = 87.0, p < 0.001χ2 = 0.2, p = 0.66BDI-II score (mean(sd))5.7 (6.5)7.2 (8.0)t = − 4.5, p < 0.0017.2 (5.4)8.3 (5.6)t = − 5.5, p < 0.0016.6 (5.9)7.9 (6.7)t = − 6.9, p < 0.001t = − 7.2, p < 0.001PHQ-9 score (mean(sd))NANANA12.4 (3.5)13.3 (3.6)t = − 6.4, p < 0.001NANANANAAbuse† (N(%))152 (15.9%)206 (19.9%)χ2 = 5.2, p = 0.022209 (14.4%)282 (18.9%)χ2 = 10.5, p = 0.001361 (15.0%)488 (19.3%)χ2 = 15.7, p < 0.001χ2 = 1.2, p = 0.27rs4588 (N(%))CC478 (50%)520 (50%)χ2 = 0.02, p = 0.99704 (49%)723 (48%)χ2 = 0.05, p = 0.971 182 (49%)1 243 (49%)χ2 = 0.01, p = 0.99χ2 = 1.0, p = 0.61CA401 (42%)437 (42%)627 (43%)646 (43%)1 028 (43%)1 083 (43%)AA78 (8%)83 (8%)116 (8%)123 (9%)194 (8%)206 (8%)5-HTTLPR (N(%))SS195 (20%)212 (20%)χ2 = 0.89, p = 0.64305 (21%)337 (23%)χ2 = 0.98, p = 0.61500 (21%)549 (22%)χ2 = 0.93, p = 0.63χ2 = 1.5, p = 0.47SL475 (50%)535 (51%)725 (50%)733 (49%)1 200 (50%)1 268 (50%)LL287 (30%)293 (29%)417 (29%)422 (28%)704 (29%)715 (28%)Vitamin D level (mean(sd))NANANA24.5 (9.3)24.4 (10.0)t = 0.19, p = 0.85NANANANANA, not available in the cohort.†None versus at least mild abus, t-test for metric data, χ2-test for non-metric data.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D moderates the interaction between 5-HTTLPR and childhood abuse in depressive disorders

Study design awaiting verification · Scientific Reports · 2020

Original publication title

Vitamin D moderates the interaction between 5-HTTLPR and childhood abuse in depressive disorders

Sarah Bonk; Johannes Hertel; Helena U. Zacharias; Jan Terock; Deborah Janowitz; Georg Homuth; Matthias Nauck; Henry Völzke; Henriette Meyer zu Schwabedissen; Sandra Van der Auwera; Hans Jörgen Grabe

© The Author(s) 2020

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

A complex interplay between genetic and environmental factors determines the individual risk of depressive disorders. Vitamin D has been shown to stimulate the expression of the tryptophan hydroxylase 2 (TPH2) gene, which is the rate-limiting enzyme for serotonin production in the brain. Therefore, we investigate the hypothesis that serum vitamin D levels moderate the interaction between the serotonin transporter promotor gene polymorphism (5-HTTLPR) and childhood abuse in depressive disorders. Two independent samples from the Study of Health in Pomerania (SHIP-LEGEND: n = 1 997; SHIP-TREND-0: n = 2 939) were used.

Depressive disorders were assessed using questionnaires (BDI-II, PHQ-9) and interview procedures (DSM-IV). Besides serum vitamin D levels (25(OH)D), a functional polymorphism (rs4588) of the vitamin D-binding protein is used as a proxy for 25(OH)D. S-allele carriers with childhood abuse and low 25(OH)D levels have a higher mean BDI-II score (13.25) than those with a higher 25(OH)D level (9.56), which was not observed in abused LL-carriers. This significant three-way interaction was replicated in individuals with lifetime major depressive disorders when using the rs4588 instead of 25(OH)D (p = 0.0076 in the combined sample).

We conclude that vitamin D relevantly moderates the interaction between childhood abuse and the serotonergic system, thereby impacting vulnerability to depressive disorders.

Authors’ abstract

A complex interplay between genetic and environmental factors determines the individual risk of depressive disorders. Vitamin D has been shown to stimulate the expression of the tryptophan hydroxylase 2 (TPH2) gene, which is the rate-limiting enzyme for serotonin production in the brain. Therefore, we investigate the hypothesis that serum vitamin D levels moderate the interaction between the serotonin transporter promotor gene polymorphism (5-HTTLPR) and childhood abuse in depressive disorders. Two independent samples from the Study of Health in Pomerania (SHIP-LEGEND: n = 1 997; SHIP-TREND-0: n = 2 939) were used.

Depressive disorders were assessed using questionnaires (BDI-II, PHQ-9) and interview procedures (DSM-IV). Besides serum vitamin D levels (25(OH)D), a functional polymorphism (rs4588) of the vitamin D-binding protein is used as a proxy for 25(OH)D. S-allele carriers with childhood abuse and low 25(OH)D levels have a higher mean BDI-II score (13.25) than those with a higher 25(OH)D level (9.56), which was not observed in abused LL-carriers. This significant three-way interaction was replicated in individuals with lifetime major depressive disorders when using the rs4588 instead of 25(OH)D (p = 0.0076 in the combined sample).

We conclude that vitamin D relevantly moderates the interaction between childhood abuse and the serotonergic system, thereby impacting vulnerability to depressive disorders.

Publication and source details

Original title: Vitamin D moderates the interaction between 5-HTTLPR and childhood abuse in depressive disorders

Sarah Bonk; Johannes Hertel; Helena U. Zacharias; Jan Terock; Deborah Janowitz; Georg Homuth; Matthias Nauck; Henry Völzke; Henriette Meyer zu Schwabedissen; Sandra Van der Auwera; Hans Jörgen Grabe

Scientific Reports · 2020

© The Author(s) 2020https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100002347Bundesministerium für Bildung und Forschung01ZX1912A01ZX1614EZacharias Helena U. Van der Auwera Sandra Projekt DEAL

Open Access funding enabled and organized by Projekt DEAL.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T14:58:40.094988+00:00

DOI: 10.1038/s41598-020-79388-7 · PMC7769965